Table 3 APOE polymorphism in T2DM patients with or without CVD
From: Apolipoprotein E gene polymorphism and the risk of cardiovascular disease and type 2 diabetes
Genotype | All case | CVD- | p | CVD+ | p | ||
|---|---|---|---|---|---|---|---|
T2DM- (n = 211) | T2DM+ (n = 247) | T2DM- (n = 232) | T2DM+ (n = 234) | ||||
E2/E2 | 5 (0.5%) | 1 (0.5%) | 2 (0.8%) | 1.00 | 1 (0.4%) | 1 (0.4%) | 1.00 |
E3/E3 | 626 (67.7%) | 160 (75.8%) | 183 (74.1%) | 0.67 | 144 (62.1.5%)## | 139 (59.4%)&& | 0.56 |
E4/E4 | 11 (11.9%) | 1 (0.5%) | – | – | 6 (2.6%) | 4 (1.7%) | 0.51 |
E2/E3 | 83 (8.9%) | 24 (11.4%) | 16 (6.5%) | 0.06 | 23 (9.9%) | 20 (8.5%) | 0.63 |
E2/E4 | 22 (2.3%) | – | 3 (1.2%) | – | 12 (5.2%) | 7 (3.0%) | 0.23 |
E3/E4 | 177(19.2%) | 25 (11.8%) | 43 (17.4%) | 0.10 | 46 (19.8%)# | 63 (26.9%)&& | 0.07 |
ε2 | 115 (6.2%) | 26 (6.2%) | 23 (4.7%) | 0.31 | 37 (7.9%) | 29 (6.1%) | 0.29 |
ε3 | 1512 (81.8%) | 369 (87.4%) | 425 (86.0%) | 0.53 | 357 (76.9%)## | 361 (77.1%)&& | 0.94 |
ε4 | 221 (12.0%) | 27 (6.4%) | 46 (9.3%) | 0.11 | 70 (15.1%)## | 78 (16.7%)&& | 0.51 |